Could there be a gleevec for brain cancer?
(Columbia University Medical Center) The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically designed to target an abnormal molecule--a fusion of two normal cell proteins--that fueled a tumor's growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 9, 2015 Category: Cancer & Oncology Source Type: news
A new approach to fighting chronic myeloid leukemia
(Ecole Polytechnique Fédérale de Lausanne) Chronic myeloid leukemia is caused by the hyperactivity of a mutated enzyme. EPFL scientists have discovered an indirect way to regulate this enzyme that could prove more effective than current therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 17, 2014 Category: Cancer & Oncology Source Type: news
Reasons for TKI Discontinuation ID ’ d in Chronic Myeloid Leukemia
Treatment - free remission maintained in 14 of 21 patients who discontinued tyrosine kinase inhibitors (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news
Neil Shah, MD, PhD: How I Treat Chronic Myeloid LeukemiaNeil Shah, MD, PhD: How I Treat Chronic Myeloid Leukemia
Jerald Radich, MD, poses a series of questions on the management of chronic myeloid leukemia to Neil Shah, MD, PhD, who describes his approach to managing the disease. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 16, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
Mother who blamed her bruising and back ache on her recent pregnancy discovers she is actually battling LEUKAEMIA
Melissa Lawson, 19, from Wirral, Merseyside, was diagnosed with chronic myeloid leukaemia after noticing bruising on her legs and being referred for tests at the Royal Liverpool University Hospital. (Source: the Mail online | Health)
Source: the Mail online | Health - September 16, 2014 Category: Consumer Health News Source Type: news
Blueprint for next generation of chronic myeloid leukemia treatment
(University of Utah Health Sciences) Researchers at Huntsman Cancer Institute at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 20, 2014 Category: Global & Universal Source Type: news
Musculoskeletal Pain on Stopping Imatinib: Should We Worry?Musculoskeletal Pain on Stopping Imatinib: Should We Worry?
A first report on a withdrawal syndrome documents patients with chronic myelogenous leukemia with musculoskeletal pain after imatinib withdrawal. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 31, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Lower-Cost Generic Drugs Gain Ground in CML
MILAN (MedPage Today) -- In the battle over generic targeted therapies for chronic myeloid leukemia (CML), the no-names won a round in a small retrospective study from Turkey. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 15, 2014 Category: American Health Source Type: news
One cell's meat is another cell's poison: How the loss of a cell protein favors cancer cells while harming healthy cells
As a new therapeutic approach, Janus kinases are currently in the limelight of cancer research. The focus of interest is the protein JAK2. By inhibiting this protein one tries to cure chronic bone marrow diseases, such as myelofibrosis and chronic myeloid leukemia (CML). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 30, 2014 Category: Science Source Type: news
Deadly Virus Meets Deadly Cancer With Hopeful Results
The history of the first hundred years of cancer therapy is that of a war, pitting bigger surgeries and stronger poisons against tumors, with patients caught in the middle. Over the last two decades, researchers have found ways of fighting cancer more precisely. One of the most successful examples is that of Gleevec (NYSE:NVS). Chronic myelogenous leukemia (CML), a kind of blood cancer, had been a tough disease to treat, even after the discovery of the genetic quirk responsible for its devastation. In the 90s, researchers discovered a chemical that specifically blocked the molecule produced by this abnormal gene and were a...
Source: Forbes.com Healthcare News - May 17, 2014 Category: Pharmaceuticals Authors: Peter Lipson Source Type: news
Real-time Quantification Assay to Monitor BCR-ABL1 Transcripts in Chronic Myeloid Leukemia
The BCR-ABL1 fusion gene, the causative lesion of chronic myeloid leukemia (CML) in >95 % of newly presenting patients, offers both a therapeutic and diagnostic target. Reverse-transcription quantitative polymerase chain reaction technology (RT-qPCR), utilizing primer–probe combinations directed to exons flanking the breakpoint junctional region, offers very high levels of both specificity and sensitivity, in a scalable, robust, and cost-effective assay. (Source: Springer protocols feed by Genetics/Genomics)
Source: Springer protocols feed by Genetics/Genomics - April 17, 2014 Category: Genetics & Stem Cells Source Type: news
BioLineRx set to begin investigator-initiated Phase I/II trial of leukaemia drug
Israeli clinical-stage biopharmaceutical firm BioLineRx is set to start an investigator-initiated Phase I/II clinical trial of its clinical-stage drug candidate BL-8040 for the treatment of patients with chronic myeloid leukaemia (CML), a cancer of w… (Source: Drug Development Technology)
Source: Drug Development Technology - April 14, 2014 Category: Pharmaceuticals Source Type: news
Bosutinib in (Ph+) Chronic Myelogenous LeukemiaBosutinib in (Ph+) Chronic Myelogenous Leukemia
Owing to its favorable toxicity profile and its high antileukemic activity, bosutinib is a promising novel treatment option for patients with CML. Therapeutic Advances in Hematology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 20, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Teva Gets Full FDA Approval for Leukemia Injection
Teva Pharmaceutical Industries announced last week that the U.S. FDA granted full approval of Synribo to treat chronic myeloid leukemia. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 18, 2014 Category: Pharmaceuticals Source Type: news
Gold Nanoparticle-Enhanced Electroporation for Leukemia Cell Transfection
Electroporation serves as an attractive nonviral gene delivery approach for its effectiveness, operational simplicity, and no restrictions of probe or cell type. The commercial electroporation systems have been widely adopted in research and clinics with protocols usually compromising appropriate transfection efficiency and cell viability. By introducing gold nanoparticles (AuNPs), we demonstrated greatly enhanced performance of electroporation from two aspects: the highly conductive, naked AuNPs help reduce the potential drop consumed by the electroporation solution so that the majority of the applied voltage of an electr...
Source: Springer protocols feed by Genetics/Genomics - February 13, 2014 Category: Genetics & Stem Cells Source Type: news
